TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05191446

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped alcohol intervention (SAT) to reduce unhealthy alcohol use
Description: Step 1 includes three sessions of motivational interviewing (MI). MI will consist of three video (Zoom) or telephone sessions: an initial 45-minute session, followed by two 20-minute sessions. Treatment is based on Motivational Interviewing by Miller and Rollnick, and includes exploring ambivalence about change, reflective listening, expressing empathy, and discussion about change. To support increased motivation to reduce drinking, discussion will center on effects of hazardous drinking on liver disease.~Step 2 includes referral to addiction medicine for participants who do not reduce unhealthy alcohol use. Specialty addiction services include both direct treatment and coordination of addiction care. After an evaluation, the addiction medicine physician may recommend pharmacotherapy (in consultation with hepatology provider if indicated), and/or referral to intensive outpatient, or residential level of care depending on clinical judgement.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care (UC)
Description: UC participants will receive their usual services in hepatology. They will also be given publicly available patient education materials regarding risk associated with unhealthy drinking (mail/email or in-person if desired) and will be asked to follow up with their physician should they have questions about information provided in the handouts. UC participants' hepatology provider will be notified if AUDIT-C scores are greater than 3 at baseline. All UC participants will have access to alcohol and other substance use treatment available to patients at their respective sites.
Study: NCT05265026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: A training session consists of 40 minutes as follows: 4x4 minutes at \> 85% of heart rate maximum (HRmax) alternated by 3x3 minutes active recovery at (50-70% of HRmax) and a 10-min-warm-up (60-79% of HRmax) and 5- minute cool-down at \~ warm up intensity. HRmax was determined during the VO2max test at baseline visit. Minutes spent in the different heart rate zones is monitored during the session (zone 1: 60-69%, zone 2: 70-74%, zone 3: 75-79%, zone 4: 80-84%, zone 5: \>85% of HRmax).
Study: NCT06192615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual Dexmedetomidine
Description: Sublingual dexmedetomidine (120 μg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Placebo
Description: Intravenous placebo of 0.9% saline administered over 40 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Placebo
Description: Intravenous placebo of 0.9% saline administered over 40 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual Placebo
Description: Inert sublingual film

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sublingual Placebo
Description: Inert sublingual film
Study: NCT06557512

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Stereotactic Radiosurgery (SRS)
Description: Undergo Hypofractionated Stereotactic Radiosurgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Description: Undergo CT imaging
Study: NCT06566326

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol and ketamine
Description: Patients received IV sedation using prepared mixture of propofol and ketamine in ratio (4:1). It is prepared by mixing 0.8 mg/kg propofol with 0.2 mg/kg ketamine (4:1) in an IV bolus, followed by half of the initial dose every 3 minutes as needed for sedation. The desired level of sedation was achieved (more than score 4) using Modified Ramsay sedation score) before allowing endoscopiest to start the procedure, then the score was assessed every 3 minutes before giving of top up doses of ketofol 4:1 (half of the initial dose) if needed, then the range and median of modified Ramsay sedation score was calculated.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Oropharyngeo-esophygeal Topical Anesthesia by OPETA Prototype tool
Description: Topicalization was done for anterior tonsillar pillar on both sides and posterior 1/3 of tongue and posterior pharyngeal wall using xylocain gel 5 % on tip of his index or middle finger then after 5-7 min. patient inserted his middle finger deeply into his mouth as a test for tolerability before insertion of OPETA tool. While head tilted forward, Lubricated OPETA device, soaked with 10 ml lidocaine 2 % mixed with adrenaline 1/200000 was gradually placed by patient with assistance from anesthetist \& patients swallowing into esophagus. To ensure effective topical anesthesia and patient tolerance, pack was left in place for 3-5 min. before being moved up, down, clockwise \& anti-clockwise.. If necessary, increments of 5 ml of 2% lidocaine/adrenaline mixture was injected through device until patient is comfortable. Maximum LA dose was kept at 5 mg/kg.
Study: NCT05305495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG
Description: Patients who fulfill the inclusion criteria will receive an intravenous dose of 1.0-1.5 mg/kg of furosemide (≤120 mg) and urine output will be monitored for three hours. Those with a urine output \< 300 ml in the first two hours post furosemide administration will receive a single oral dose of 25 mg of empagliflozin. Two hours after taking empagliflozin, patients will receive a second intravenous dose of 1.0-1.5 mg/kg of furosemide with another timed urine collection at three hours. Empagliflozin will then be continued daily for five days or until hospital discharge, unless the treating physician considers this not to be clinically appropriate.
Study: NCT04059757

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT)
Description: 1 dose = 30 capsules on day 1 of Fecal Microbiota Transplantation
Study: NCT05817539

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid balance negativation
Description: During the RRT, UFnet will be settled on 2ml/kg/h and adapted to hemodynamic tolerance and tissue perfusion .~When the patient's baseline body weight is reached the UF net will be settled to maintain it.~In case of failure of the fluid balance negativation after 24h, UFnet will be settled on 3ml/kg/h. Then when the baseline body weight is reached UFnet will be settled on 0.5 et 1ml/kg/h or if necessary adapted to 1,5ml/kg/h to maintain it~In case of hemodynamic intolerance (NADN \> 0,5 µg/kg/min) or tissue hypoperfusion, UF net will be stopped during 6 hours and restarted if NADN \< 0,5 µg/kg/min and without tissue hypoperfusion.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Body weight Stabilization
Description: During the RRT, UFnet will be settled between 0 et 1 ml/kg/h and adapted in case of weight stabilization failure or hemodynamic intolerance.~In case of weight stabilisation failure ( variation \>3% after 24h), the UF net can be increased to 1,5 ml/kg/h, as long as high intakes require UFnette at 1.5mL/kg/h to stabilize water balance, with daily reassessment.~In case of hemodynamic intolerance (NADN \> 0,5 µg/kg/min), UF net will be stopped during 6 hours and restarted if NADN \< 0,5 µg/kg/min.
Study: NCT05449587

Intervention type: OTHER
Intervention: MRI and PRO
Description: MRI as a standard of care for the analysis of silent rupture. BREAST-Q Postoperative Augmentation module scales to record patients for satisfaction: Satisfaction with breasts; Satisfaction with outcome; Psychosocial well-being; Physical well-being
Study: NCT05300724

Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be administered in this study.
Study: NCT06082960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9911
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9911
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9911
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9911
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Administered intravenously
Study: NCT06399861

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Incubator ambient relative humidity (RH) of 70%
Description: The incubator will be set to an ambient relative humidity (RH) of 70%.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Incubator ambient relative humidity (RH) of 90%
Description: The incubator will be set to an ambient relative humidity (RH) of 90%.
Study: NCT05096156

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precision1® Daily Disposable Contact Lens
Description: Soft, spherical contact lens used to correct distance vision.
Study: NCT04876040

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SSO2 Downstream System
Description: 60-min adjunctive reperfusion of hyperoxemic blood into target coronary artery, immediately following revascularization by means of PCI with stenting.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI + Impella
Description: Standard of Care Intervention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI + Impella
Description: Standard of Care Intervention
Study: NCT05861128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib
Description: Participants will receive 100 mg Jaktinib orally twice daily for 32 weeks
Study: NCT05950737

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy
Description: All patients have undergone completion neck dissection following SNB in the process of standardization.
Study: NCT06128434

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: zinc carbonate nano-hydroxyapatite toothpaste
Description: Participants will brush their teeth with zinc carbonate nano-hydroxyapatite toothpaste twice daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 8% arginine toothpaste
Description: Participants will brush their teeth with 8% arginine toothpaste twice daily.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride toothpaste
Description: Participants will brush their teeth with Fluoride toothpaste twice daily.
Study: NCT06472960

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate-intensity cycling
Description: Moderate-intensity cycling on Ergoline Ergoselect 100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vigorous-intensity cycling
Description: Vigorous-intensity cycling on Ergoline Ergoselect 100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Uninterrupted sitting
Description: Uninterrupted sitting in a quiet room

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Uninterrupted sitting
Description: Uninterrupted sitting in a quiet room

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Uninterrupted sitting
Description: Uninterrupted sitting in a quiet room
Study: NCT05191121

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FTP Alone
Description: Participants will be challenged with training speed, weight, limited therapist support, and context variation (e.g., fine motor activities will vary using objects such as cards, dice, coins).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FTP+Con-FES
Description: Participants will be challenged with training speed, weight, limited therapist support, and context variation (e.g., fine motor activities will vary using objects such as cards, dice, coins). Muscle groups will be stimulated at the same time they would be activated naturally in a pre-injury movement pattern utilizing conventional parameter FES.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FTP+WPHF-FES
Description: Participants will be challenged with training speed, weight, limited therapist support, and context variation (e.g., fine motor activities will vary using objects such as cards, dice, coins). Muscle groups will be stimulated at the same time they would be activated naturally in a pre-injury movement pattern utilizing wide pulse, high frequency parameter FES.
Study: NCT04337034

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile phone supported and family-centred rehabilitation
Description: Participants in the intervention group will receive an eight-week mobile phone supported and family-centred rehabilitation intervention (F@ce 2.0).The participants will be introduced to a problem-solving strategy intended to facilitate the learning and problem-solving process to be used during the intervention. The strategy will provide a structure for healthcare professionals delivering the intervention. Three targets (goals) in daily activities will be formulated that the person wants and needs to do within the home environment. Each activity will be practiced together with the healthcare professionals and family members. Family members will be informed about the participant's target activities and the planned strategies for reaching the targets. The participants will practice the target activities in their home environment supported by mobile phone calls and SMS. In addition they will be given information about stroke and their blood pressure will be measured.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Information and blood pressure measurement
Description: Control group participants will be given information about stroke and their blood pressure will be measured.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Information and blood pressure measurement
Description: Control group participants will be given information about stroke and their blood pressure will be measured.
Study: NCT05986799

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Amway Herbal Drink
Description: 1 sachet per time, 3 times daily, for 3 months period.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Drink
Description: 1 sachet per time, 3 times daily, for 3 months period.
Study: NCT06258447

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Autologous bone marrow mononuclear cells processed / delivered using the CardiAMP cell therapy system
Description: the ABM MNC is obtained from the study patient via bone marrow aspiration in the hip and processed and delivered using the CardiAMP cell therapy system during the cardiac catheterization.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cells processed / delivered using the CardiAMP cell therapy system
Description: the ABM MNC is obtained from the study patient via bone marrow aspiration in the hip and processed and delivered using the CardiAMP cell therapy system during the cardiac catheterization.
Study: NCT06589453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal elevator with digital nasoalveolar molding in bilateral cleft lip and palate infants
Description: This is a unique nasal elevator aiming to improve nasolabial esthetics in conjunction with digital nasoalveolar molding appliance when used in bilateral cleft lip and palate infants.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal stent with digital nasoalveolar molding in bilateral cleft lip and palate infants
Description: Nasal stent that is used in conjunction with digital nasoalveolar molding in bilateral cleft lip and palate infants
Study: NCT05579197

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lower-limb robotic intervention
Description: The intervention proposed in this study involves the use of an exosuit for lower limbs, the Myosuit. The selection of the tasks has been done in order to replicate typical activities of daily living in a structured environment, i.e. a rehabilitation hospital.~Specifically, the tasks involve walking, sit to stand, balance and stair climbing.~During the phases of assessment (session 2 and session 10), other devices are be used. Specifically:~* The Optogait system; for a markerless gait analysis;~* The Gyko sensor; an inertial sensor that will be used at the beginning of the training for the synchronisation of the signals recorded by the Myosuit and the signal recorded by the Optogait.~Finally, during all the sessions, the Polar heart rate sensor is used to constantly monitor the cardiac frequency of the patients.
Study: NCT06398496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Aerobic exercise intervention will involve multiple exercise sessions completed (unsupervised) by participants. Exercise programs will be given to participants, matched to their current level of fitness as determined via a maximal cardiorespiratory fitness test, and will be adjusted via progressive overload every 1-2 weeks by an exercise and sports science professional.
Study: NCT04990973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Average American Diet (AAD)
Description: Participants will follow specified diet requirements.~Macronutrient targets for the AAD will be approximately 35-37% of energy from fat (13.5% from saturated fat), 15% from protein, and 48-50% from carbohydrates (10 g fiber/d for an average 2000 kcal/d diet).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Average American Diet (AAD)
Description: Participants will follow specified diet requirements.~Macronutrient targets for the AAD will be approximately 35-37% of energy from fat (13.5% from saturated fat), 15% from protein, and 48-50% from carbohydrates (10 g fiber/d for an average 2000 kcal/d diet).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: Participants will follow specified diet requirements.~Macronutrient targets for the Mediterranean diet will be approximately 40% of energy from fat (8.5% from saturated fat), 20% of energy from protein, and 40% from carbohydrates (40 g fiber/d for an average 2000 kcal/d diet).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: Participants will follow specified diet requirements.~Macronutrient targets for the Mediterranean diet will be approximately 40% of energy from fat (8.5% from saturated fat), 20% of energy from protein, and 40% from carbohydrates (40 g fiber/d for an average 2000 kcal/d diet).
Study: NCT04652570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VB119
Description: Humanized, immunoglobin (Ig) G1 monoclonal antibody (mAb) to be administered as intravenous infusion at multiple timepoints during the study.
Study: NCT05149742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive and audiometry evaluation
Description: For both Patients and controls:~* Cognitive functions evaluation~* Tonal and vocal audiometry~* Self questionnaires

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive and audiometry evaluation
Description: For both Patients and controls:~* Cognitive functions evaluation~* Tonal and vocal audiometry~* Self questionnaires
Study: NCT06544187

Intervention type: DIAGNOSTIC_TEST
Intervention: MRS scan
Description: Magnetic Resonance Spectroscopy scan on the thigh
Study: NCT06242392

Intervention type: GENETIC
Intervention: homologous recombination deficiency
Description: Homologous Recombination Deficiency (HRD) refers to a disruption or deficiency in the homologous recombination repair (HRR) pathway, which is a crucial mechanism in cells for repairing DNA double-strand breaks (DSBs). This pathway is particularly important for maintaining genomic stability.

Intervention type: GENETIC
Intervention: homologous recombination deficiency
Description: Homologous Recombination Deficiency (HRD) refers to a disruption or deficiency in the homologous recombination repair (HRR) pathway, which is a crucial mechanism in cells for repairing DNA double-strand breaks (DSBs). This pathway is particularly important for maintaining genomic stability.
Study: NCT05320718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 20 ml of 0.5% ropivacaine as bolus and a programmed intermittent bolus of 10 ml ropivacaine 0.2% every 2 h after surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 20 ml of 0.5% ropivacaine as bolus and a programmed intermittent bolus of 10 ml ropivacaine 0.2% every 2 h after surgery
Study: NCT06544187

Intervention type: DIAGNOSTIC_TEST
Intervention: MRS scan
Description: Magnetic Resonance Spectroscopy scan on the thigh

Intervention type: DIAGNOSTIC_TEST
Intervention: CPET
Description: Cardiopulmonary Exercise Test

Intervention type: DIAGNOSTIC_TEST
Intervention: CPET
Description: Cardiopulmonary Exercise Test
Study: NCT06288061

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive Neuromodulation
Description: This intervention group will receive neuromodulation treatment two days a week for a total of six sessions.~The patient is placed in the supine position with a cushion under the knees. The physiotherapist will be positioned behind the patient's head on the side to be treated. The technique will be applied on both anterolateral sides of the neck, where the Phrenic nerve passes in front of the anterior Scalene, between the Subclavian arteries and veins. Neuromodulation will be applied with a Pointer Excel II. It will be applied with negative polarity, at a frequency of 2 Hertz (HZ) and with a current intensity varying between 0 and 45 milliamperes (mA). The intensity shall be increased progressively until the patient's diaphragmatic contraction can be observed without pain. The technique shall be applied on each side for a total of 8 minutes, divided into intervals of 10 seconds of stimulation and 20 seconds of rest.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cervico-dorsal Massage
Description: This intervention group will receive manual therapy two days a week for a total of six sessions.~The patient shall be placed prone position with a cushion under his or her feet. This group will receive manual therapy on the entire posterior cervical and dorsal region, the area between the occipital bone, the shoulders and the scapulae. The massage will be carried out with a little oil or cream for about 20 minutes.
Study: NCT04916925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Adding vitamin D to PCOS patients who are resistant to clomiphene regime for induction will or not improve the Clinical pregnancy rate and will or not increase chances of ovulation and pregnancy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomid
Description: CLOMID is adrug used for ovulation induction
Study: NCT04674098

Intervention type: DEVICE
Intervention: The Beat Analytics System (BAS)
Description: There are three subsystems to the BAS; data aggregation, data analysis and data presentation.